Delaware Health News Online: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Delaware Health News Online.

Press releases published on April 2, 2026

Apr. 2, 2026

Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium

Indeterminate GlobeNewswire

Apr. 2, 2026

Catheter Precision Engages Strategic Advisor

Indeterminate GlobeNewswire

Apr. 2, 2026

Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026

Indeterminate GlobeNewswire

Apr. 2, 2026

Emergent BioSolutions Participates in Upcoming International Preparedness Conferences

Indeterminate GlobeNewswire

Apr. 2, 2026

Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive

Indeterminate GlobeNewswire

Apr. 2, 2026

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

Apr. 2, 2026

Bionano Announces Publication from Johns Hopkins and MD Anderson Showing that OGM can Outperform Traditional Methods in Analysis of Multiple Myeloma

Indeterminate GlobeNewswire

Apr. 2, 2026

Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer 

Indeterminate GlobeNewswire

Apr. 2, 2026

Commure Introduces Dictation: AI-Powered Clinical Voice, Now at the Cursor

Indeterminate GlobeNewswire

Apr. 2, 2026

Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives

Indeterminate GlobeNewswire

Apr. 2, 2026

MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy

Indeterminate GlobeNewswire

Apr. 2, 2026

Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer

Indeterminate GlobeNewswire

Apr. 2, 2026

Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections

Indeterminate GlobeNewswire

Apr. 2, 2026

Cylinder Health launches Stool Scan to innovate and standardize one of GI care’s most subjective signals

Indeterminate GlobeNewswire

Apr. 2, 2026

Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs

Indeterminate GlobeNewswire

Apr. 2, 2026

Cartesian Therapeutics Announces New Employment Inducement Grants

Indeterminate GlobeNewswire

Apr. 2, 2026

Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)

Indeterminate GlobeNewswire

Apr. 2, 2026

Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response

Indeterminate GlobeNewswire

Apr. 2, 2026

Neutrolis Announces Positive First-in-Human Phase 1a Results from LIBERATE-I Trial of NTR-1011, a First-in-Class DNASE1L3 Fusion Protein

Indeterminate GlobeNewswire

Apr. 2, 2026

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

Indeterminate GlobeNewswire